We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Parkinson's Disease Genome Study Data Made Available to Researchers

By Biotechdaily staff writers
Posted on 18 Mar 2008
Raw data obtained during the first genome-wide association study (GWAS) to focus on Parkinson's disease will become only the second dataset on Parkinson's disease to be made available through dbGaP, the database of Genotypes and Phenotypes operated by the [U.S.] National Library of Medicine's National Center for Biotechnology Information.

This first genome-wide association study applied to Parkinson's disease was funded under the Michael J. More...
Fox Foundation for Parkinson's Research (MJFF) Linked Efforts to Accelerate Parkinson's Solutions (LEAPS) initiative. Investigators at the Mayo Clinic (Rochester, MN, USA) in collaboration with colleagues at Perlegen Sciences, Inc. (Mountain View, CA, USA) carried out the study.

The [U.S.] National Human Genome Research Institute (NHGRI) and the [U.S.] National Center for Biotechnology Information (NCBI), both components of the [U.S.] National Institutes of Health (NIH), are sponsoring release of the GWAS data.

"Until now, the individual-level data from this study had been available only to a few researchers,” said Dr.Teri Manolio, director of the NHGRI Office of Population Genomics. "This is the first orphan data set NHGRI is adopting to make public through NCBI, but it certainly will not be the last. We appreciate the willingness of the LEAPS researchers and patients to share their data with the rest of the research community and hope it will increase our understanding of Parkinson's disease.”

"It's wonderful that NHGRI has agreed to facilitate access to this data by researchers around the globe working on Parkinson's disease,” said principal investigator Dr. Demetrius Maraganore, a neurologist at the Mayo Clinic. "Our hope is that these data will be used to make breakthroughs in the prevention and treatment of this devastating disease.”


Related Links:
Mayo Clinic
Perlegen Sciences
National Center for Biotechnology Information dbgap

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.